Cystic Fibrosis Therapeutics Market size to cross USD 79.7 billion by 2035

The global cystic fibrosis therapeutics market was valued at USD 18.1 billion in 2025 and is expected to grow from USD 20.9 billion in 2026 to USD 79.7 billion in 2035, at a CAGR of 16%, according to the latest report published by Global Market Insights, Inc.

Increasing incidence rate of the cystic fibrosis patient population.

The increasing incidence of cystic fibrosis among the global patient population is becoming a major factor driving demand for advanced treatment options and long-term disease management solutions. Rising awareness regarding genetic disorders, improvements in diagnostic technologies, and wider access to newborn screening programs are contributing to earlier and more accurate diagnosis of cystic fibrosis. As the number of diagnosed patients continues to increase, healthcare systems and pharmaceutical companies are placing greater emphasis on developing effective therapies that can improve patient outcomes, extend life expectancy, and enhance quality of life.

Advancements in CFTR modulator therapy.

Advancements in CFTR modulator therapy are significantly transforming the cystic fibrosis treatment landscape by targeting the underlying genetic cause of the disease rather than only managing symptoms. Continuous innovation in precision medicine and targeted therapies has led to the development of highly effective CFTR modulators that improve lung function, reduce pulmonary complications, and enhance overall patient health. These therapies enable more personalized treatment approaches and are demonstrating improved clinical outcomes for a broader range of cystic fibrosis mutations.

High treatment costs.

Adverse side effects associated with current cystic fibrosis therapies remain a significant challenge for both patients and healthcare providers, potentially limiting treatment adherence and long-term effectiveness. Many existing therapies may cause complications such as gastrointestinal discomfort, liver-related issues, respiratory irritation, and drug interactions, which can negatively affect patient quality of life and overall treatment experience. In some cases, prolonged use of medications may also lead to reduced tolerability or additional health concerns, particularly among patients requiring complex combination therapies. These limitations are increasing the demand for safer, more targeted, and better-tolerated treatment alternatives.

Browse key industry insights spread across 149 pages with 159 market data tables and figures from the report, Cystic Fibrosis Therapeutics Market, “By Type (Medication, Non-Medication), By Age Group (Below 18 Years, 18–40 Years, 41 & Above), Growth Forecast” in detail, along with the table of contents:  

https://www.gminsights.com/industry-analysis/cystic-fibrosis-therapeutics-market

Rising Adoption Among Below 18 Years

The below 18 years age group accounted for 76.9% share in 2025, driven by the high prevalence of conditions such as cystic fibrosis (CF) among children and adolescents. Since CF and similar genetic disorders often manifest early in life, timely diagnosis and early intervention become critical, thereby increasing the demand for specialized pediatric treatment approaches and personalized care solutions within this population segment. In addition, heightened awareness among caregivers, improved diagnostic capabilities, and broader access to innovative therapies are further strengthening the dominance of this segment. Growing emphasis on pediatric clinical research, along with supportive regulatory pathways for child-focused treatments, continues to reinforce its leading position throughout the forecast period.

Medication to Gain Traction

The medication segment generated USD 16.2 billion in 2025. This segment includes key drug classes such as CFTR modulators, bronchodilators, mucolytic agents, anti-infective therapies, pancreatic enzyme supplements, and other supportive medications. Strong growth in advanced drug development, particularly CFTR modulator therapies and symptomatic treatment options, is significantly boosting demand within this segment. These medications are designed to improve patient outcomes by targeting both the underlying genetic mutations and the associated respiratory and digestive symptoms of cystic fibrosis, thereby enhancing overall disease management and quality of life.

North America to Emerge as a Propelling Region

North America cystic fibrosis therapeutics market held a 74.5% share in 2025 supported by the strong presence of major pharmaceutical companies, ensuring broad availability and access to advanced treatment options. In addition, favorable reimbursement structures and comprehensive insurance coverage systems make high-cost cystic fibrosis therapies more accessible to patients. The region also benefits from well-established newborn screening programs and strong institutional support from organizations such as the Cystic Fibrosis Foundation, which actively promotes research, innovation, and early treatment adoption.

The global cystic fibrosis therapeutics market includes several leading companies such as Alcresta Therapeutics, Baxter, Chiesi Farmaceutici, F. Hoffmann-La Roche, Gilead Sciences, Koninklijke Philips, Lupin, Monaghan Medical, Novartis, Savara, Sionna Therapeutics, Teva Pharmaceutical Industries, and Vertex Pharmaceuticals.

Companies operating in the cystic fibrosis therapeutics market are focusing on continuous innovation in CFTR modulator therapies and next-generation precision medicines to improve treatment efficacy and patient outcomes. Leading players are investing heavily in research and development to expand their drug pipelines and target a broader range of genetic mutations. Strategic collaborations with research institutes, hospitals, and patient advocacy organizations are helping accelerate clinical trials and regulatory approvals. Market participants are also adopting lifecycle management strategies, including combination therapies and improved formulations, to extend product value.

In April 2026, Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration approved the use of ALYFTREK for treating people with cystic fibrosis aged 6 years and older who had a CFTR gene variant that was either responsive based on clinical or in vitro data or that resulted in the production of CFTR protein.